Cardioprotective Properties of Omecamtiv Mecarbil against Ischemia and Reperfusion Injury

Omecamtiv mecarbil (OM) is a first-in-class myosin activator. It was developed as a new inotropic therapy option for heart failure and is currently the object of a phase 3 clinical trial program. OM activates ryanodine receptors, which were shown to be involved in cardioprotection induced by conditi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Med
Main Authors: Stroethoff, Martin, Behmenburg, Friederike, Meierkord, Simon, Bunte, Sebastian, Mayer, Felix, Mathes, Alexander, Heinen, André, Hollmann, Markus W., Huhn, Ragnar
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6463149/
https://ncbi.nlm.nih.gov/pubmed/30889854
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm8030375
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados